Pharmacotherapy of Psychosis and Mania

Pharmacotherapy of psychosis and mania encompasses the systematic treatment of severe mental health disorders using targeted medications. This comprehensive course, developed by JoVE Coach, examines antipsychotic drugs for treating schizophrenia, delusional disorders, and other psychotic conditions, alongside mood stabilizers for managing bipolar disorder and manic episodes in US clinical practice.

• Understand the pathophysiology of schizophrenia, including dopamine, serotonin, and glutamate hypotheses
• Identify the clinical manifestations of psychosis, including positive and negative symptoms
• Learn the mechanisms of action of typical and atypical antipsychotic medications
• Explore therapeutic goals for acute and chronic psychotic disorder management
• Analyze side effects and safety considerations of first- and second-generation antipsychotics
• Apply knowledge of mood stabilizers including lithium, anticonvulsants, and antipsychotics for mania
• Understand treatment-resistant cases and alternative therapeutic approaches
• Examine drug selection criteria based on patient-specific factors and clinical conditions

1. Psychotic Disorders and Schizophrenia Pathophysiology The dopamine hypothesis remains central to understanding schizophrenia, where excessive dopaminergic activity in mesolimbic pathways produces positive symptoms like hallucinations and delusions. Conversely, reduced dopamine activity in mesocortical regions contributes to negative symptoms including anhedonia and cognitive impairment. The serotonin hypothesis suggests that 5-HT2A receptor dysfunction contributes to psychotic symptoms, while the glutamate hypothesis proposes that NMDA receptor hypofunction leads to downstream dopaminergic abnormalities. Understanding these interconnected neurotransmitter systems is crucial for comprehending how different antipsychotic medications target specific aspects of schizophrenia pathophysiology in American psychiatric practice.

2. First-Generation (Typical) Antipsychotic Mechanisms Typical antipsychotics, including chlorpromazine and haloperidol, primarily block dopamine D2 receptors throughout the brain. Clinical efficacy occurs when 60-75% of D2 receptors are occupied, effectively reducing positive symptoms of psychosis. However, receptor occupancy exceeding 78% frequently causes extrapyramidal side effects including dystonia, parkinsonism, and tardive dyskinesia. These medications demonstrate high affinity for D2 receptors but limited selectivity, leading to therapeutic effects accompanied by significant motor side effects. The antiemetic properties result from D2 receptor blockade in the medullary chemoreceptor trigger zone, making these drugs useful for treating nausea and vomiting in US emergency departments.

3. Second-Generation (Atypical) Antipsychotic Advantages Atypical antipsychotics like risperidone, olanzapine, and lurasidone offer superior therapeutic profiles by blocking both D2 and 5-HT2A receptors. This dual antagonism produces effective antipsychotic action with reduced extrapyramidal side effects compared to typical agents. Many atypical drugs also function as partial 5-HT1A agonists, providing anxiolytic benefits. Clozapine, reserved for treatment-resistant schizophrenia in US psychiatric hospitals, demonstrates unique efficacy but requires regular blood monitoring due to agranulocytosis risk. The improved side effect profile of atypical antipsychotics has made them first-line treatments in American psychiatric practice, though metabolic side effects including weight gain and diabetes remain concerning.

4. Acute and Chronic Treatment Strategies Short-term antipsychotic treatment focuses on rapid symptom control in conditions like delirium, dementia with behavioral disturbances, and acute psychotic episodes. Low doses of high-potency agents minimize side effects while providing effective symptom relief. Chronic treatment of schizophrenia and delusional disorders requires long-term antipsychotic maintenance to prevent relapse, with studies showing significantly reduced hospitalization rates in compliant patients. Long-acting injectable formulations help address medication adherence challenges common in US community mental health settings. Treatment-resistant cases may require clozapine therapy or electroconvulsive therapy, with careful monitoring protocols established by American psychiatric guidelines.

5. Bipolar Disorder and Antimanic Pharmacotherapy Mania treatment utilizes mood stabilizers including lithium carbonate, anticonvulsants, and antipsychotic medications. Lithium remains the gold standard for bipolar disorder prophylaxis, inhibiting inositol monophosphatase and affecting multiple neurotransmitter systems. Therapeutic lithium levels (0.6-1.2 mEq/L) require careful monitoring, as toxicity occurs above 1.5 mEq/L and may necessitate dialysis in US emergency departments. Anticonvulsants like valproic acid, carbamazepine, and lamotrigine provide alternative mood stabilization, particularly useful in rapid-cycling bipolar disorder. Combination therapy with antipsychotics offers rapid antimanic effects while mood stabilizers provide long-term prophylaxis, following evidence-based treatment algorithms used in American psychiatric practice.